To facilitate a more in-depth and comprehensive understanding of the Company among a broad base of investors, the Company is scheduled to hold its 2024 Annual Online Performance Presentation on Friday...
Recently, Beilu Pharmaceutical (300016) released the "2025 First Quarter Report". Building on the stable growth in annual performance in 2024, Beilu Pharmaceutical has had a great start in 2...
Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) issued by the Netherlands Medicines Evaluation Board (MEB) in accordance with the relevant regula...
Recently, Hichi Pharmaceutical's iopamidol API received the "Approval Notice for the Marketing Application of Chemical APIs" from the National Medical Products Administration. This is an...
Recently, Zhejiang Hichi Pharmaceutical Corporation Limited, a subsidiary of Beijing Beilu Pharmaceutical Co., Ltd., received the product registration certificate for Iodixanol API issued by the Korea...